Research, conferences, and FDA actions.

摘要

A phase 3 trial that compared the efficacy and safety of ustekinumab (Stelara) and etanercept (Enbrel) in the treatment of moderate to severe plaque psoriasis showed that over 12 weeks, 67.5 percent of ustekinumab patients experienced at least a 75 percent improvement in the psoriasis area and severity index, compared with 56.8 percent of etanercept patients. Ustekinumab also demonstrated efficacy in patients who were unresponsive to etanercept.